Man

Pamela Victoria Salman Boghikian

Líneas de Investigación


Educación

  •  Médico cirujano, UNIVERSIDAD DE CHILE. Chile, 1992
  •  Licenciatura en medicina, UNIVERSIDAD DE CHILE. Chile, 1990
  •  Medicina interna, UNIVERSIDAD DE CHILE. Chile, 1995
  •  Oncología Médica, UNIVERSIDAD DE CHILE. Chile, 1999
  •  Entrenamiento de especialización (Oncología), UNIV TEXAS M.D. ANDERSON CANCER CENTER. Chile, 2001

Experiencia Profesional

  •   Encargada de protocolos de investigación oncológica Part Time

    Hospital J.J. Aguirre

    Chile

    1997 - A la fecha

  •   Directora del comité de ética Part Time

    Grupo Oncológico Cooperativo Chileno de Investigación (GOCCHI)

    Santiago, Chile

    2002 - A la fecha

  •   Creadora y directora de la unidad de estudios clínicos Part Time

    Fundación Arturo López Pérez

    Santiago, Chile

    2008 - 2017

  •   Médico Oncólogo Senior Part Time

    Centro Oncológico OncoVIDA

    Santiago, Chile

    2020 - A la fecha

  •   Jefa de la Unidad de Ensayos Clínicos Part Time

    Centro Oncológico OncoVIDA

    Santiago, Chile

    2020 - A la fecha

  •   Médico Senior en Oncología Médica Part Time

    Hospital San Juan de Dios

    Santiago, Chile

    2020 - A la fecha

  •   Subdirector médico Part Time

    Centro Oncológico OncoVIDA

    Santiago, Chile

    2020 - A la fecha

Formación de Capital Humano


Supervisión Formal de Estudiantes/Practicantes

Angélica de la Macarena Molina Oñate (Médico Oncólogo) Fundación Arturo López Pérez
Sergio Enrique Panay Serra ((Médico Oncólogot) Fundación Arturo Lopez Perez
Carlos Romero Sanchez (Médico Oncólogo) Centro Oncológico OncoVIDA
Elizabeth Milla Ramirez (Médico Oncólogo) Fundación Arturo López Pérez
Jaime Andres Anabalon Toha (Médico Oncólogo) Clínica Alemana de Santiago
Christopher Joseph Tabilo Heavey (Médico Oncólogo y Hematólogo) Clínica Red Salud



 

Article (48)

Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)

Tannir, Nizar M.; Formiga, Maria Nirvana; Penkov, Konstantin; Kislov, Nikolay; Vasiliev, Aleksandr; Skare, Nils Gunnar; Hong, Walter; Dai, Stanley; Tang, Lily; Qureshi, Anila; Zalevsky, Jonathan; Tagliaferri, Mary A.; George, Daniel; Agarwal, Neeraj; Pal, Sumanta

Article ISI
JOURNAL OF CLINICAL ONCOLOGY  (2024)

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Saad, Fred; Vjaters, Egils; Shore, Neal; Olmos, David; Xin, Nianzeng; Pereira de Santana Gomes, Andrea Juliana; de Andrade Mota, Augusto Cesar; Salman, Pamela; Jievaltas, Mindaugas; Ulys, Albertas; Jakubovskis, Maris; Kopyltsov, Evgeny; Han, Weiqing et al.

Article
JOURNAL OF CLINICAL ONCOLOGY  (2024)

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial

Tewari, Krishnansu S.; Colombo, Nicoletta; Monk, Bradley J.; Mendoza, I.; Cáceres, M. Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yañez, Eduardo; Gumus, Mahmut; de Mendoza, M. Olivera Hurtado; Samouëlian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Tekin, Cumhur; Li, Kan; Toker, Sarper; Keefe, Stephen M.; Lorusso, Domenica

Article SCOPUS
JAMA Oncology  (2024)

Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study

Lorusso, Domenica; Colombo, Nicoletta; Dubot, C.; Cáceres, M.V.; Hasegawa, K.; Shapira-Frommer, R.; Salman, Pamela; Yañez, E; Gümü?, M.; Olivera Hurtado de Mendoza, M. et al.

Article
ANNALS OF ONCOLOGY  (2024)

A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus

Janjigian, Yelena Y.; Shitara, Kohei; Moehler, Markus; Garrido, Marcelo; Salman, Pamela; Wyrwicz, Lucjan; Yamaguchi, Kensei; Skoczylas, Tomasz; Bragagnoli, Arinilda Campos; Liu, Tianshu; Schenker, Michael; Yanez, Patricio; Tehfe, Mustapha; Kowalyszyn, Ruben; Karamouzis, Michalis V.; Bruges, Ricardo; Zander, Thomas; Pazo-Cid, Roberto; Hitre, Erika; Feeney, Kynan; Cleary, James M.; Poulart, Valerie; Cullen, Dana; Lei, Ming; Xiao, Hong; Kondo, Kaoru; Li, Mingshun; Ajani, Jaffer A.

Article ISI
FUTURE ONCOLOGY  (2023)

First-Line Pembrolizumab plus Chemotherapy Versus Placebo plus Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Monk, Bradley J.; Colombo, Nicoletta; Tewari, Krishnansu S.; Dubot, Coraline; Caceres, M. Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yanez, Eduardo; Gumus, Mahmut; de Mendoza, Mivael Olivera Hurtado; Samouelian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Tekin, Cumhur; Li, Kan; Keefe, Stephen M.; Lorusso, Domenica; KEYNOTE-826 Investigators

Article ISI
JOURNAL OF CLINICAL ONCOLOGY  (2023)

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo- controlled, phase 3 trial

Monk, Bradley J.; Tewari, Krishnansu S.; Dubot, Coraline; Caceres, M. Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yanez, Eduardo; Guemues, Mahmut; Mendoza, Mivael Olivera Hurtado de; Samouelian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Tekin, Cumhur; Li, Kan; Nguyen, Allison Martin; Monberg, Matthew J.; Colombo, Nicoletta; Lorusso, Domenica

Article ISI
LANCET ONCOLOGY  (2023)

KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER

Monk, Bradley J.; Colombo, Nicoletta; Tewari, Krishnansu Sujata; Dubot, Coraline; Caceres, M. Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yanez, Eduardo; Gumus, Mahmut; De Mendoza, Mivael Olivera Hurtado; Samouelian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Tekin, Cumhur; Li, Kan; Keefe, Stephen Michael; Lorusso, Domenica

Article ISI
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  (2023)

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

Long, Georgina V.; Hodi, F. Stephen; Lipson, Evan J.; Schadendorf, Dirk; Ascierto, Paolo A.; Matamala, Luis; Salman, Pamela; Castillo Gutiérrez, Erika; Rutkowski, Piotr; Gogas, Helen J.; Lao, Christopher D.; Janoski De Menezes, Juliana; Dalle, Stéphane; Arance, Ana; Grob, Jean-Jacques; Keidel, Sarah; Shaikh, Anadil; Sobiesk, Anne Marie; Dolfi, Sonia; Tawbi, Hussein A.

Article
NEJM Evidence  (2023)

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial (Reprinted from vol 28, pg 1061, 2010)

Sternberg, Cora N.; Davis, Ian D.; Mardiak, Jozef; Szczylik, Cezary; Lee, Eunsik; Wagstaff, John; Barrios, Carlos H.; Salman, Pamela; Gladkov, Oleg A.; Kavina, Alexander; Zarba, Juan J.; Chen, Mei; McCann, Lauren; Pandite, Lini; Roychowdhury, Debasish F.; Hawkins, Robert E.

Article ISI
JOURNAL OF CLINICAL ONCOLOGY  (2023)

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial

Kelley, Robin Kate; Ueno, Makoto; Yoo, Changhoon; Finn, Richard S.; Furuse, Junji; Ren, Zhenggang; Yau, Thomas; Klumpen, Heinz-Josef; Chan, Stephen L.; Ozaka, Masato; Verslype, Chris; Bouattour, Mohamed; Park, Joon Oh; Barajas, Olga; Pelzer, Uwe; Valle, Juan W.; Yu, Li; Malhotra, Usha; Siegel, Abby B.; Edeline, Julien; Vogel, Arndt; KEYNOTE-966 Investigators

Article ISI
LANCET  (2023)

PEMBROLIZUMAB plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: BEVACIZUMAB SUBGROUP ANALYSIS BASED ON PROTOCOL-SPECIFIED FINAL OVERALL SURVIVAL RESULTS OF KEYNOTE-826

Lorusso, Domenica; Colombo, Nicoletta; Monk, Bradley J.; Dubot, Coraline; Caceres, Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yanez, Eduardo; Gumus, Mahmut; De Mendoza, Mivael Olivera Hurtado; Samouelian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Li, Kan; Toker, Sarper; Tekin, Cumhur; Tewari, Krishnansu S.

Article ISI
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  (2023)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, Sun Young; Oh, Do-Youn; Yanez, Patricio; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernandez, Manuel Gonzalez; Li, Jin; Lowery, Maeve A.; Cil, Timucin; Cruz, Felipe Melo; Qin, Shukui; Luo, Suxia; Pan, Hongming; Wainberg, Zev A.; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Wyrwicz, Lucjan S.; KEYNOTE-859 Investigators

Article ISI
LANCET ONCOLOGY  (2023)

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047

Hodi, F. S.; Tawbi, H. A.; Lipson, E. J.; Schadendorf, D.; Ascierto, P. A.; Matamala, L. A.; Salman, P.; Gutierrez, E. C.; Rutkowski, P.; Gogas, H. J.; Lao, C. D.; Menezes, J.; Dalle, S.; Arance Fernandez, A. M.; Grob, J. J.; Keidel, S.; Rodriguez, S.; Wang, P.; Dolfi, S.; Long, G. V.

Article ISI
ANNALS OF ONCOLOGY  (2022)

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Tawbi, Hussein A.; Schadendorf, Dirk; Lipson, Evan J.; Ascierto, Paolo A.; Matamala, Luis; Gutierrez, Erika Castillo; Rutkowski, Piotr; Gogas, Helen J.; Lao, Christopher D.; De Menezes, Juliana Janoski; Dalle, Stephane; Arance, Ana; Grob, Jean-Jacques; Srivastava, Shivani; Abaskharoun, Mena; Hamilton, Melissa; Keidel, Sarah; Simonsen, Katy L.; Sobiesk, Anne Marie; Li, Bin; Hodi, F. Stephen; Long, Georgina, V; RELATIVITY-047 Investigators

Article ISI
NEW ENGLAND JOURNAL OF MEDICINE  (2022)

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

Gerstein, Hertzel C.; Sattar, Naveed; Rosenstock, Julio; Ramasundarahettige, Chinthanie; Pratley, Richard; Lopes, Renato D.; Lam, Carolyn S. P.; Khurmi, Nardev S.; Heenan, Laura; Del Prato, Stefano; Dyal, Leanne; Branch, Kelley; AMPLITUDE-O Trial Investigators

Article ISI
NEW ENGLAND JOURNAL OF MEDICINE  (2021)

Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries

Toledo Pereira, Felipe Moraes; Goncalves e Silva, Adriano; Abbade Dettino, Aldo Lourenco; Garcia Cardoso, Ana Paula; Sasse, Andre Deeke; Kann, Ariel Galapo; Dzik, Carlos; Herchenhorn, Daniel; Fontes Jardim, Denis Leonardo; Lopera, Diego; Ayadi, Mouna; Salman, Pamela; Manneh Kopp, Ray Antonio; De Carvalho, Ricardo Saraiva; De Araujo Cavallero, Sandro Roberto; Aguiar, Sergio; Souza, Vinicius Carrera; Uson, Pedro Luiz Serrano, Jr.; Soares, Andrey

Article ISI
JCO GLOBAL ONCOLOGY  (2021)

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.

Moehler, Markus H.; Shitara, Kohei; Garrido, Marcelo; Salman, Pamela; Shen, Lin; Wyrwicz, Lucjan; Yamaguchi, Kensei; Skoczylas, Tomasz; Bragagnoli, Arinilda Silva Campos; Liu, Tianshu; Schenker, Michael; Yanez, Patricio Eduardo; Tehfe, Mustapha; Li, Mingshun; Cullen, Dana; Memaj, Arteid; Lei, Ming; Xiao, Hong; Janjigian, Yelena Y.; Ajani, Jaffer A.

Article ISI
JOURNAL OF CLINICAL ONCOLOGY  (2021)

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Janjigian, Yelena Y.; Shitara, Kohei; Moehler, Markus; Garrido, Marcelo; Salman, Pamela; Shen, Lin; Wyrwicz, Lucjan; Yamaguchi, Kensei; Skoczylas, Tomasz; Bragagnoli, Arinilda Campos; Liu, Tianshu; Schenker, Michael; Yanez, Patricio; Tehfe, Mustapha; Kowalyszyn, Ruben; Karamouzis, Michalis V.; Bruges, Ricardo; Zander, Thomas; Pazo-Cid, Roberto; Hitre, Erika; Feeney, Kynan; Cleary, James M.; Poulart, Valerie; Cullen, Dana; Lei, Ming; Xiao, Hong; Kondo, Kaoru; Li, Mingshun; Ajani, Jaffer A.

Article ISI
LANCET  (2021)

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Paz-Ares, Luis; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Sakai, Hiroshi; Lingua, Alejo; Salman, Pamela; Souquet, Pierre-Jean; De Marchi, Pedro; Martin, Claudio; Perol, Maurice; Scherpereel, Arnaud; Lu, Shue; John, Thomas; Carbone, David P.; Meadows-Shropshire, Stephanie; Agrawal, Shruti; Oukessou, Abderrahim; Yan, Jinchun; Reck, Martin

Article ISI
LANCET ONCOLOGY  (2021)

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Reck, Martin; Ciuleanu, Tudor-Eliade; Lee, Jong-Seok; Schenker, Michael; Audigier-Valette, Clarisse; Zurawski, Bogdan; Linardou, Helena; Otterson, Gregory A.; Salman, Pamela; Nishio, Makoto; Jimenez, Emmanuel de la Mora; Lesniewski-Kmak, Krysztof; Albert, Istvan; Ahmed, Samreen; Syrigos, Konstantinos; Penrod, John R.; Yuan, Yong; Blum, Steven, I; Nathan, Faith E.; Sun, Xiaowu; Moreno-Koehler, Alejandro; Taylor, Fiona; O'Byrne, Kenneth John

Article ISI
JOURNAL OF THORACIC ONCOLOGY  (2021)

KEYNOTE-826: PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER

Colombo, N.; Dubot, C.; Lorusso, D.; Caceres, V.; Hasegawa, K.; Shapira-Frommer, R.; Tewari, K.; Salman, P.; Usta, E. Hoyos; Yanez, E.; Gumus, M.; de Mendoza, M. Olivera Hurtado; Samouelian, V.; Castonguay, V.; Arkhipov, A.; Toker, S.; Li, K.; Keefe, S.; Monk, B.

Article ISI
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  (2021)

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Colombo, N.; Dubot, C.; Lorusso, D.; Caceres, M., V; Hasegawa, K.; Shapira-Frommer, R.; Tewari, K. S.; Salman, P.; Usta, E. Hoyos; Yanez, E.; Gumus, M.; de Mendoza, M. Olivera Hurtado; Samouelian, V; Castonguay, V; Arkhipov, A.; Toker, S.; Li, K.; Keefe, S. M.; Monk, B. J.; KEYNOTE-826 Investigators

Article ISI
NEW ENGLAND JOURNAL OF MEDICINE  (2021)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study

Colombo, N.; Dubot, C.; Lorusso, D.; Caceres, V.; Hasegawa, K.; Shapira-Frommer, R.; Tewari, K. S.; Salman, P.; Hoyos, E.; Yanez, E.; Gumus, M.; De Mendoza, M. Olivera Hurtado; Samouelian, V.; Castonguay, V.; Arkhipov, A.; Toker, S.; Li, K.; Keefe, S. M.; Monk, B. J.

Article ISI
ANNALS OF ONCOLOGY  (2021)

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety

Villanueva, Luis; Anabalon, Jaime; Butte, Jean M.; Salman, Pamela; Panay, Sergio; Milla, Elizabeth; Gallardo, Carlos; Hoefler, Sebastian; Charles, Roberto; Reyes, Felipe; Barajas, Olga; Matamala, Luis; Molina, Angelica; Portino, Sergio; Berrios, Marcela; Caglevic, Christian; Mahave, Mauricio

Article ISI
ECANCERMEDICALSCIENCE  (2021)

Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Moehler, M.; Shitara, K.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Campos Bragagnoli, A.; Liu, T.; Schenker, M.; Yanez, P.; Tehfe, M.; Poulart, V.; Cullen, D.; Lei, M.; Kondo, K.; Li, M.; Ajani, J. A.; Janjigian, Y. Y.

Article ISI
ANNALS OF ONCOLOGY  (2020)

Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1

Brahmer, J. R.; Ciuleanu, T-E.; Schenker, M.; Audigier-Valette, C.; Zurawski, B.; Linardou, H.; Kim, S-W.; Otterson, G. A.; Salman, P.; De La Mora Jimenez, E.; Lesniewski-Kmak, K.; Ahmed, S.; Albert, I.; Barlesi, F.; Feeney, K.; Frickhofen, N.; Li, A.; Sun, P.; Hellmann, M.

Article ISI
ANNALS OF ONCOLOGY  (2020)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Motzer, Robert J.; Escudier, Bernard; McDermott, David F.; Frontera, Osvaldo Aren; Melichar, Bohuslav; Powles, Thomas; Donskov, Frede; Plimack, Elizabeth R.; Barthelemy, Philippe; Hammers, Hans J.; George, Saby; Gruenwald, Viktor; Porta, Camillo; Neiman, Victoria; Ravaud, Alain; Choueiri, Toni K.; Rini, Brian, I; Salman, Pamela; Kollmannsberger, Christian K.; Tykodi, Scott S.; Grimm, Marc-Oliver; Gurney, Howard; Leibowitz-Amit, Raya; Geertsen, Poul F.; Amin, Asim; Tomita, Yoshihiko; McHenry, M. Brent; Saggi, Shruti Shally; Tannir, Nizar M.

Article ISI
JOURNAL FOR IMMUNOTHERAPY OF CANCER  (2020)

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Motzer, Robert; Rini, Brian, I; McDermott, David F.; Frontera, Osvaldo Aren; Hammers, Hans J.; Carducci, Michael A.; Salman, Pamela; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta, Camillo; George, Saby; Neiman, Victoria; Bracarda, Sergio; Tykodi, Scott S.; Barthelemy, Philippe; Leibowitz-Amit, Raya; Plimack, Elizabeth R.; Oosting, Sjoukje F.; Redman, Bruce; Melichar, Bohusiav; Powles, Thomas; Nathan, Paul; Oudard, Stephan; Pook, David; Choueiri, Toni K.; Donskov, Frede; Grimm, Marc-Oliver; Gurney, Howard; Heng, Daniel Y. C.; Kollmannsberger, Christian K.; Harrison, Michael R.; Tamita, Yoshihiko; Duran, Ignacio; Gruenwold, Viktor; McHenry, M. Brent; Mekan, Sabeen; Tannir, Nizar M.; CheckMate 214 Investigators

Article ISI
LANCET ONCOLOGY  (2019)

Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America

Queiroz Muniz D.; Ratto B.; Yang H.; Zhao J.; Jenkins M.; Signorovitch J.; Dezzani L.; Salman P.; Lema Medina M.; Lopera D.; Lerzo G.; del Castillo C.; Chacon M.; Martin A.; Campos-Gomez S.

Article ISI SCOPUS
ADVANCES IN THERAPY  (2019)

Complete preoperative chemotherapy regimen FLOT: Evaluating the safety and histopathologic results in gastric cancer (GC).

Villanueva, Luis; Anabalon, Jaime; Barajas, Olga; Gallardo, Carlos; Leal, Jose Luis; Mahave, Mauricio; Matamala, Luis; Molina, Angelica; Reyes, Felipe; Salman, Pamela; Butte, Jean M.; Charles, Roberto; Devaud, Nicolas; Hoefler, Sebastian; Enrique Panay, Sergio; Milla, Elizabeth; Alejandra Munoz, Maria; Caglevic, Christian

Article ISI
JOURNAL OF CLINICAL ONCOLOGY  (2018)

Evidence of response to pembrolizumab in a patient with lynch syndrome-related metastatic colon cancer

Salman P.; Panay S.; Fernández R.; Mahave, M; Soza-Ried C.

Article ISI SCOPUS
 (2018)

Nivolumab (nivo) plus ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

Hellmann, Matthew D.; Ciuleanu, Tudor Eliade; Pluzanski, Adam; Lee, Jong Seok; Otterson, Gregory; Audigier-Valette, Clarisse; Minenza, Elisa; Linardou, Helena; Burgers, Sjaak; Salman, Pamela; Borghaei, Hossein; Ramalingam, Suresh S.; Brahmer, Julie; Reck, Martin; O'Byrne, Kenneth J.; Geese, William J.; Green, George; Chang, Han; Szustakowski, Joseph D.; Bhagavatheeswaran, Prabhu; Healey, Diane; Fu, Yali; Nathan, Faith; Paz-Ares, Luis

Article ISI
CANCER RESEARCH  (2018)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Hellmann, MD; Ciuleanu, TE; Pluzanski, A; Lee, JS; Otterson, GA; Audigier-Valette, C; Minenza, E; Linardou, H; Burgers, S; Salman, P; Borghaei, H; Ramalingam, SS; Brahmer, J; Reck M.; OByrne, KJ; Geese, WJ; Green, G; Chang, H; Szustakowski, J; Bhagavatheeswaran, P; Healey, D; Fu, Y; Nathan, F; Paz-Ares, L

Article ISI SCOPUS
NEW ENGLAND JOURNAL OF MEDICINE  (2018)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, RJ; Tannir, NM; McDermott, DF; Frontera, OA; Melichar, B; Choueiri, TK; Plimack, ER; Barthelemy, P; Porta, C; George, S; Powles, T; Donskov, F; Neiman, V; Kollmannsberger, CK; Salman, P; Gurney, H; Hawkins, R; Ravaud, A; Grimm, MO; Bracarda, S; Barrios, CH; Tomita, Y; Castellano, D; Rini, BI; Chen, AC; Mekan, S; McHenry, MB; Wind-Rotolo, M; Doan, J; Sharma, P; Hammers, HJ; Escudier, B

Article ISI SCOPUS
NEW ENGLAND JOURNAL OF MEDICINE  (2018)

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

von Minckwitz, Gunter; Procter, Marion; de Azambuja, Evandro; Zardavas, Dimitrios; Benyunes, Mark; Viale, Giuseppe; Suter, Thomas; Arahmani, Amal; Rouchet, Nathalie; Clark, Emma; Knott, Adam; Lang, Istvan; Levy, Christelle; Yardley, Denise A.; Bines, Jose; Gelber, Richard D.; Piccart, Martine; Baselga, Jose; APHINITY Steering Comm

Article ISI
NEW ENGLAND JOURNAL OF MEDICINE  (2017)

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

Sonnenblick A.; Agbor-Tarh D.; Bradbury I.; Di Cosimo S.; Azim H.A.; Jr.; Fumagalli D.; Sarp S.; Wolff A.C.; Andersson M.; Kroep J.; Cufer T.; Simon S.D.; Salman P.; Toi M.; Harris L.; Gralow J.; Keane M.; Moreno-Aspitia A.; Piccart-Gebhart M.; De Azambuja E.

Article ISI SCOPUS
JOURNAL OF CLINICAL ONCOLOGY  (2017)

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial

Hecht J.R.; Bang Y.-J.; Qin S.K.; Chung H.C.; Xu J.M.; Park J.O.; Jeziorski K.; Shparyk, Y; Hoff P.M.; Sobrero A.; Salman, P; Li, J; Protsenko S.A.; Wainberg Z.A.; Buyse M.; Afenjar K.; Houè V.; Garcia, A.; Kaneko, T; Huang, Y; Khan-Wasti S.; Santillana, S; Press M.F.; Slamon D.

Article ISI SCOPUS
JOURNAL OF CLINICAL ONCOLOGY  (2016)

The initial Chilean experience with 68Ga/177Lu-PSMA in castration resistant prostate cancer

Amaral, Horacio; Lavados, Hugo; Fernandez, Rene; Kramer, Vasko; Ribbeck, Jessica; Salman, Pamela; Sandoval, Camilo; Caglevic, Christian; Pinto, Iván

Article
World Journal of Nuclear Medicine (Online)  (2016)

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Choueiri, T. K.; Escudier, B.; Powles, T.; Mainwaring, P. N.; Rini, B. I.; Donskov, F.; Hammers, H.; Hutson, T. E.; Lee, J-L; Peltola, K.; Roth, B. J.; Bjarnason, G. A.; Geczi, L.; Keam, B.; Maroto, P.; Heng, D. Y. C.; Schmidinger, M.; Kantoff, P. W.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G. M.; Tannir, N. M.; Motzer, R. J.; METEOR Investigators

Article ISI
NEW ENGLAND JOURNAL OF MEDICINE  (2015)

Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx)

Bang, Yung-Jue; Qin, Shukui; Chung, Hyun-Choel; Xu, Jian-Ming; Park, Joon Oh; Jeziorski, Krzysztof; Shparyk, Yaroslav; Hoff, Paulo M.; Sobrero, Alberto F.; Salman, Pamela; Li, Jin; Protsenko, Svetlana; Buyse, Marc E.; Afenjar, Karen; Houe, Vincent; Garcia, Agathe; Huang, Yingjie; Armour, Alison; Slamon, Dennis J.; Hecht, J. Randolph

Article ISI
JOURNAL OF CLINICAL ONCOLOGY  (2015)

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

Sternberg, CN; Hawkins, RE; Wagstaff, J; Salman, P; Mardiak J.; Barrios, CH; Zarba, JJ; Gladkov, OA; Lee, E; Szczylik, C; McCann, L; Rubin, SD; Chen M.; Davis, ID

Article ISI SCOPUS
European Journal of Cancer  (2013)

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Lordick, Florian; Kang, Yoon-Koo; Chung, Hyun-Cheol; Salman, Pamela; Oh, Sang Cheul; Bodoky, Gyoergy; Kurteva, Galina; Volovat, Constantin; Moiseyenko, Vladimir M.; Gorbunova, Vera; Park, Joon Oh; Sawaki, Akira; Celik, Ilhan; Goette, Heiko; Melezinkova, Helena; Moehler, Markus; AIO EXPAND Investigators

Article ISI
LANCET ONCOLOGY  (2013)

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Sternberg, CN; Davis, ID; Mardiak J.; Szczylik, C; Lee, E; Wagstaff, J; Barrios, CH; Salman, P; Gladkov, OA; Kavina, A; Zarba, JJ; Chen M.; McCann, L; Pandite, L; Roychowdhury, DF; Hawkins, RE

Article ISI
JOURNAL OF CLINICAL ONCOLOGY  (2010)

BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST

Canals L, Mauricio; Fernández G, Monzerrat; Barros R, Adolfo; Mahave C, Mauricio; Salman B, Pamela; Yañez G, Manuel

Article SCIELO
Revista chilena de radiología  (2009)

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Pirker, Robert; Pereira, Jose R.; Szczesna, Aleksandra; von Pawel, Joachim; Krzakowski, Maciej; Ramlau, Rodryg; Vynnychenko, Ihor; Park, Keunchil; Yu, Chih-Teng; Ganul, Valentyn; Roh, Jae-Kyung; Bajetta, Emilio; O'Byrne, Kenneth; de Marinis, Filippo; Eberhardt, Wilfried; Goddemeier, Thomas; Emig, Michael; Gatzemeier, Ulrich; Pirker, R.; Thatcher, N.; Armand, J. P.; Camus, P.; Victor, N.; Emig, M.; Mueser, M.; Pilz, K.; Goddemeier, T.; Montaner, I.; Lachs, Martin; Hoang-Sayag, Loan; Alvarez, A.; Coppola, F.; Recondo, G.; Richardet, E.; Kirsten, F.; Karapetis, C.; Parente, P.; Michael, M.; White, S.; Boyce, A.; Lewis, C.; Slancar, M.; Pavlakis, N.; Abdi, E.; Underhill, C.; Pittman, K.; Burghuber, O.; Ruckser, R.; Ulsperger, E.; Kolb, R.; Humblet, Y.; Canon, J-L.; Bustin, F.; Barrios, C.; Gorini, C.; Ferreira, C. Moreira; Pereira, J.; Ivanova, N.; Tomova, A.; Tzekova, V.; Chilingirov, P.; Racheva, M.; Gill, M.; Orlandi, F. Javier; Reyes, J.; Salman, P.; Tomiskova, M.; Roubec, J.; Pesek, M.; Musil, J.; Zatloukal, P.; Robinet, G.; Riviere, A.; Moro-Sibilot, D.; Barlesi, F.; Chouaid, C.; Tourani, J-M.; Lena, H.; Thiberville, L.; Quoix, E.; Schott, R.; Lemarie, E.; Schlimok, G.; Loddenkemper, R.; Eberhardt, W.; Wilke, H.; Martens, U.; Waller, C.; von Pawel, J.; Griesinger, F.; Gatzemeier, U.; Schuette, W.; Eschbach, C.; Bischoff, H.; Chemaissani, A.; Wolf, J.; Fischer, J.; Bohnet, S.; Klein, H.; Kortsik, C.; Peschel, C.; Ittel, T. H.; Fett, W.; Chua, D.; Magyar, P.; Ostoros, G.; Somfay, A.; Vinkler, I.; Papai, Z.; Szima, B.; Mark, Z.; Tehenes, S.; O'Byrne, K.; Brandes, A.; Martoni, A.; Marini, G.; Artioli, F.; Bajetta, E.; Siena, S.; de Marinis, F.; Santoro, A.; Barni, S.; Berchem, G.; Arrieta, O.; Figueroa, J.; Martinez, L.; Llerena, E.; Burgers, J. A.; Giaccone, G.; Schramel, F. M. N. H.; Goey, S. H.; Stigt, J. A.; Jagiello, G.; Jagiello-Gruszfeld, A.; Szczesna, A.; Ramlau, R.; Krzakowski, M.; Tomeczko, J.; Teixeira, E.; Parente, B.; Kononova, G.; Biakhov, M.; Borisov, V.; Gorbunova, V.; Konev, A.; Manzuk, L.; Lukyanov, Y.; Manikhas, G.; Orlov, S.; Heo, D-S.; Kim, S-W.; Park, K.; Roh, J-K.; Choi, J-H.; Soo, R.; Mazal, J.; Kasan, P.; Berzinec, P.; Prochazka, M.; Carrato, A.; Pivlots, R. Bastus; Lianes, P.; Villar, J.; Paz-Ares, L.; Cobo, M.; Trigo, J. M.; Ayarra, A. Gurpide; Constenla, M.; Lario, A. Paredes; Brea, M. Lopez; Insa, A.; Vivanco, G. Lopez; Brodin, O.; Wagenius, G.; Ochsenbein, A.; Rauch, D.; Knuth, A.; Chang, G-C.; Perng, R. P.; Yang, C-H.; Yu, C-T.; Demirkazik, A.; Demirelli, F.; Nicolson, M.; Falk, S.; Price, A.; Mulatero, C.; Lee, S. M.; O'Brien, M.; Gardiner, J.; Laurence, V.; Ferry, D.; Paramonov, V.; Bondarenko, I.; Pylypenko, M.; Ganul, V.; Oliynichenko, P.; Simonov, S.; Shparyk, Y.; Bashtan, V.; Vynnychenko, I.; Galaychuk, I.; Hotko, Y.; FLEX Study Team

Article ISI
LANCET  (2009)

Diagnosis of pneumonia and monitoring of infection eradication

Ruiz, M.; Arosio C.; Salman, P; Bauer, TT; Torres A.

Article ISI
DRUGS  (2000)

MALT lymphoma of the bladder: report of a case

Gallardo, J; Gamargo, C; Fodor, M; Comparini, B; Salman, P; Yanez, M

Article
REVISTA MEDICA DE CHILE  (1998)

Abstract (4)

Prospective Epidemiological Study of Metastatic Non-Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung (LACOG 0116)

Werutsky, G; Cardona, AF; Kaen, D; Arrieta, OG; Gelatti, A; Mathias, C; Zukin, M; Cronemberger, E; Mascarenhas, E; Campos, C; De Lima, VC; Borges, G; Coelho, J; Oliveira, F; Silva, A; Araujo, LH; Quiroba, A; Andrade, H; Morbeck, I; Lobaton, J; Dias, J; Zarba, J; Fein, L; Salman, P; Trejo, R; Barrios, C

Abstract ISI
JOURNAL OF THORACIC ONCOLOGY  (2019)

Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

Tannir, NM; Frontera, OA; Hammers, HJ; Carducci, MA; McDermott, DF; Salman, P; Escudier, B; Beuselinck, B; Amin, A; Porta, C; George, S; Bracarda, S; Tykodi, SS; Powles, T; Rini, BI; Tomita, Y; McHenry, MB; Mekan, SF; Motzer, RJ

Abstract ISI
JOURNAL OF CLINICAL ONCOLOGY  (2019)

Global Cancer Institute multidisciplinary tumor boards as a tool to improve patterns of clinical practice for breast and gynecologic cancer in resource-limited settings.

Louis, J; Bukowski, A; Rodrigues, AN; Moreno, J; Ferreyra, M; Lopes, A; De La Serna, F; Tindwa, CH; Mollah, OB; Villarreal-Garza, C; Duarte, C; Hambardzumyan, V; Salman, P; Soria, T; Goss, PE

Abstract ISI
JOURNAL OF CLINICAL ONCOLOGY  (2017)

Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).

Escudier, BJ; Motzer, RJ; Powles, T; Tannir, NM; Davis, ID; Donskov, F; Grunwald, V; Heng, DYC; Hutson, T; Melichar, B; Nosov, D; Rini, BI; Salman, P; Sternberg, CN; Szczylik, C; Wolter, P; Arroyo, AM; Mangeshkar, M; Agarwal, N; Choueiri, TK

Abstract ISI
JOURNAL OF CLINICAL ONCOLOGY  (2016)

ConferencePoster (20)

Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study

Tourneau, C Le; Rojas, CI; Leary, A; Yonemori, K; Lugowska, I; Tosi, D; Ghiringhelli, F; Caglevic, C; Yanez, EP; Perets, R; Rha, SY; Salman, P et al

ConferencePoster
 (2024)

Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005

Seo, S; Calderon, B; Chou, HH; Hsu, CH; Salman, P; Ghiringhelli, F; Ozyilkan, O; Rojas, CI; Sendur, M.A.N; Le Tourneau, C

ConferencePoster
 (2024)

Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

Saad, F; Vjaters, E; Shore, ND; Olmos, D; Xing, N; Gomes, A.J.P.D.S.; Mota, A.C.A.; Salman, P; Jievaltas, M; Ulys, A et al

ConferencePoster
 (2024)

Patient-reported outcomes (PROs) with coformulated vibostolimab/pembrolizumab (vibo/pembro) for metastatic cervical cancer (CC): Results from the KEYVIBE-005 study

Yonemori, K; Rojas, CI; Leary, A; Le Tourneau, C; Lugowska, I; Ozyilkan, O; Caglevic, C; Ghiringhelli, F; Yanez, EP; Dongen, MV; Perets, R; Gumus, M; Kwiatkowski, M; Rha, SY; Salman, P et al.

ConferencePoster
 (2024)

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer

Pignata, Sandro; Sukhin, Vladyslav; Colombo, Nicoletta; Korach, Jacob; Matsumoto, Takashi; Lalondrelle, Susan; Vizkeleti, Julia; Randall, Leslie; Samouelian, Vanessa; Salman, Pamela et al.

ConferencePoster
 (2024)

Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study

Toullec, C; Seo, C; Robinson, AG; Chou, HH; Salman, P; Ghiringhelli, F; Ozyilkan, O; Rojas, CI; Sendur, M.A.N; Le Tourneau, C et al

ConferencePoster
 (2024)

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Monk, Bradley J; Colombo, Nicoletta; Tewari, Krishnansu Sujata; Dubot, Coraline; Caceres, M Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yañez, Eduardo; Gumus, Mahmut et al

ConferencePoster
 (2023)

A multicohort, open-label, phase 2 basket study of the coformulation of vibostolimab with pembrolizumab, with or without other anticancer therapies, in select solid tumors

Lugowska, Iwona; Rojas, Carlos; Falcon, Alejandro; Gonzalez, Lucia; Hsu, Chih-Hung; Yen, Chia-Jui; Rha, Sun Young; Yonemori, Kan; Li, Daneng; Geva, Ravit; Salman, Pamela

ConferencePoster
 (2022)

NIVO + RELA vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : survie globale et taux de réponse objective par sous-groupes clés de l’étude RELATIVITY-047

Grob, JJ; Tawbi, HA; Hodi, S; Lipson, EJ; Schadendorf, D; Ascierto, PA; Matamala, L; Salman, P; Castillo, E; Gutiérrez, P et al

ConferencePoster
 (2022)

Nivolumab (NIVO)+ relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047

Tawbi, Hussein A; Hodi, F Stephen; Lipson, Evan J; Schadendorf, Dirk; Ascierto, Paolo; Matamala, Luis; Salman, Pamela; Castillo, Erika; Rutkowski, Piotr; Gogas, Helen

ConferencePoster
 (2022)

Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)

Monk, Bradley; Tewari, Krishnansu; Dubot, Coraline; Caceres, M Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yanez, Eduardo; Gümü?, Mahmut; Olivera, Mivael et al

ConferencePoster
 (2022)

Pembrolizumab+ chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826

Tewari, Krishnansu Sujata; Colombo, Nicoletta; Monk, Bradley J; Dubot, Coraline; Cáceres, M Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yañez, Eduardo; Gumus, Mahmut et al

ConferencePoster
 (2022)

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

Long, Georgina; Hodi, F. Stephen; Lipson, Evan; Schadendorf, Dirk; Ascierto, Paolo Antonio; Matamala, Luis; Salman, Pamela; Castillo, Erika; Rutkowski, Piotr et al

ConferencePoster
 (2022)

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

Paz-Ares, L; Ciuleanu, TE; Yu, X; Salman, P; Pluzanski, A; Nagrial, A; Havel, L et al

ConferencePoster
 (2019)

CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups

Escudier, B; Tannir, NM; McDermott, DF; Frontera, OA; Melichar, B; Plimack, ER; Barthelemy, P; George, S; Neiman, V; Porta, C; Choueiri, TK; Powles, T; Donskov, F; Salman, P; Kollmannsberger, CK

ConferencePoster
 (2017)

Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study

Lordick, Florian; Kang, Yoon-Koo; Salman, Pamela; Oh, Sang Cheul; Bodoky, Gyorgy; Kurteva, Galina Petrova; Volovat, Constantin D; Moiseyenko, Vladimir; Sawaki, Akira et al

ConferencePoster
 (2013)

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial

J Randolph Hecht,; Bang, Yung-Jue; Qin, Shukui K; Chung, Hyun C; Xu, Jianming M; Park, Joon O; Jeziorski, Krzysztof; Shparyk, Yaroslav; Hoff, Paulo M; Sobrero, Alberto; Salman, Pamela; Li, Jin

ConferencePoster
 (2013)

Cetuximab in combination with capecitabine and cisplatin as first-line treatment in advanced gastric cancer: Randomized controlled phase III EXPAND study

Lordick, F; Bodoky, G; Chung, H; Kurteva, G; Kang, YB; Oh, SC; Salman, P; Goette, H; Melezinkova, H; Moehler, M.

ConferencePoster
 (2012)

A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)

Sternberg, CN; Szczylik, C; Lee, E; Salman, P; Mardiak, J.; Davis, ID; Pandite, L; Chen M; McCann, L; Hawkins, R

ConferencePoster
 (2009)

Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer

Randall, Leslie; Sukhin, Vladyslav; Colombo, Nicoletta; Korach, Jacob; Matsumoto, Takashi; Lalondrelle, Susan; Vizkeleti, Julia; Samouelian, Vanessa; Salani, Ritu; Salman, Pamela et al

ConferencePoster
 

Letter (1)

Carvedilol for anthracycline cardiomyopathy prevention

Florenzano, F; Salman, P

Letter ISI
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY  (2007)

Review (2)

Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective

Salman, Pamela; de Melo, Andreia Cristina; Rico-Restrepo, Mariana; Rodriguez, Jeronimo; Russi, Andrea; Schmerling, Rafael Aron; Zambrano, Angela; Cinat, Gabriela

Review ISI
FRONTIERS IN ONCOLOGY  (2023)

Unraveling the complex link between vitamin D levels and cancer: A crucial understanding for designing future supplementation approaches

Salman, Pamela; Oliveira-Cruz, Luciana; Soza-Ried, Cristian

Review ISI
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES  (2023)

75
Pamela Salman

1
Sergio Portiño

1
Carlos Gallardo

JEFE TECNICO

INVESTIGACION DEL CANCER

CLINICA ONCOLOGIA FUNDACION ARTURO LOPEZ PEREZ

SANTIAGO, Chile

1
mauricio Ruiz

Jefe de Sección

Medicina Norte

Hospital Clínico Universidad de Chile

Santiago, Chile